Behind the Journey of ADCs by Raffaele Colombo
Raffaele Colombo posted on X about recent paper by him as first author titled “The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development” published on Cancer Discovery by AACR.
Authors: Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, Patricia M. LoRusso, Elisabeth G.E. de Vries
“~400 ADCs have entered clinical development since the 1980s! We represented them by the year they first entered the clinic, divided by payload classes. To capture their status, we created a spiral table, which took some patience…”
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023